HIV vs. HIV: Turning HIV-Derived Peptides into Drugs

Peptide Drug Discovery and Development: Translational Research in Academia and Industry

Volumn , Issue , 2011, Pages 209-229

  Franquelim, Henri G ^a   Matos, Pedro M ^a   Veiga, A Salomé ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiretrovirals; Fusion inhibitors; Gp41; HIV 1; Membranes; Peptides

Indexed keywords

EID: 84875652307     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527636730.ch10     Document Type: Chapter

References (91)

1. Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M. (2005) Immunobiology: The Immune System in Health and Disease, Garland Science, New York, NY.
2. UNAIDS/WHO. (2009) AIDS epidemic update 2009. http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (7 October 2010).
3. De Clercq, E. (2002) New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta, 1587 (2-3), 258-275.
4. Palella, F. J. Jr, Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., and Holmberg, S.D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med., 338 (13), 853-860.
5. Carr, A. (2003) Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov., 2 (8), 624-634.
6. Eckert, D.M. and Kim, P.S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem., 70, 777-810.
7. Center, R.J., Leapman, R.D., Lebowitz, J., Arthur, L.O., Earl, P.L., and Moss, B. (2002) Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol., 76 (15), 7863-7867.
8. Chan, D.C. and Kim, P.S. (1998) HIV entry and its inhibition. Cell, 93 (5), 681-684.
9. Wyatt, R. and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 280 (5371), 1884-1888.
10. Tamm, L.K. and Han, X. (2000) Viral fusion peptides: a tool set to disrupt and connect biological membranes. Biosci. Rep., 20 (6), 501-518.
11. Chambers, P., Pringle, C.R., and Easton, A.J. (1990) Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol., 71 (Pt 12), 3075-3080.
12. Lorizate, M., Huarte, N., Saez-Cirion, A., and Nieva, J.L. (2008) Interfacial pretransmembrane domains in viral proteins promoting membrane fusion and fission. Biochim. Biophys. Acta, 1778 (7-8), 1624-1639.
13. Montero, M., van Houten, N.E., Wang, X., and Scott, J.K. (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev., 72 (1), 54-84, table of contents
14. Lu, M., Blacklow, S.C., and Kim, P.S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol., 2 (12), 1075-1082.
15. Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell, 89 (2), 263-273.
16. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley, D.C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature, 387 (6631), 426-430.
17. Maddon, P.J., Dalgleish, A.G., McDougal, J.S., Clapham, P.R., Weiss, R.A., and Axel, R. (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell, 47 (3), 333-348.
18. Chesebro, B., Buller, R., Portis, J., and Wehrly, K. (1990) Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J. Virol., 64 (1), 215-221.
19. Clapham, P.R., Blanc, D., and Weiss, R.A. (1991) Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology, 181 (2), 703-715
20. Briz, V., Poveda, E., and Soriano, V. (2006) HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother., 57 (4), 619-627.
21. De Clercq, E. (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 33 (4), 307-320.
22. Doms, R.W. and Trono, D. (2000) The plasma membrane as a combat zone in the HIV battlefield. Genes Dev., 14 (21), 2677-2688.
23. Kilby, J.M. and Eron, J.J. (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 348 (22), 2228-2238.
24. Robertson, D. (2003) US FDA approves new class of HIV therapeutics. Nat. Biotechnol., 21 (5), 470-471.
25. Kilby, J.M., Hopkins, S., Venetta, T.M., DiMassimo, B., Cloud, G.A., Lee, J.Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M.R., Nowak, M.A., Shaw, G.M., and Saag, M.S. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med., 4 (11), 1302-1307.
26. Wild, C.T., Shugars, D.C., Greenwell, T. K., McDanal, C.B., and Matthews, T.J. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A., 91 (21), 9770-9774.
27. Kilgore, N.R., Salzwedel, K., Reddick, M., Allaway, G.P., and Wild, C.T. (2003) Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virol., 77 (13), 7669-7672.
28. Eckert, D.M. and Kim, P.S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A., 98 (20), 11187-11192.
29. Naider, F. and Anglister, J. (2009) Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol., 19 (4), 473-482.
30. Wild, C., Dubay, J.W., Greenwell, T., Baird, T. Jr, Oas, T.G., McDanal, C., Hunter, E., and Matthews, T. (1994) Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. U. S. A., 91 (26), 12676-12680.
31. Chan, D.C., Chutkowski, C.T., and Kim, P.S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A., 95 (26), 15613-15617.
32. Chang, D.K. and Hsu, C.S. (2007) Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1. Antiviral Res., 74 (1), 51-58
33. Otaka, A., Nakamura, M., Nameki, D., Kodama, E., Uchiyama, S., Nakamura, S., Nakano, H., Tamamura, H., Kobayashi, Y., Matsuoka, M., and Fujii, N. (2002) Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl., 41 (16), 2937-2940.
34. Wild, C., Greenwell, T., and Matthews, T. (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virusmediated cell-cell fusion. AIDS Res. Hum. Retroviruses, 9 (11), 1051-1053.
35. Liu, S., Wu, S., and Jiang, S. (2007) HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des., 13 (2), 143-162.
36. Jiang, S., Zhao, Q., and Debnath, A.K. (2002) Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des., 8 (8), 563-580.
37. Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., and Jiang, S. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem., 282 (13), 9612-9620.
38. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., and Jiang, S. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem., 280 (12), 11259-11273.
39. Bar, S. and Alizon, M. (2004) Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J. Virol., 78 (2), 811-820.
40. Veiga, S., Henriques, S., Santos, N.C. and Castanho, M. (2004) Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem. J., 377 (Pt 1), 107-110
41. Kliger, Y. and Shai, Y. (2000) Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J. Mol. Biol., 295 (2), 163-168.
42. Rimsky, L.T., Shugars, D.C., and Matthews, T.J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol., 72 (2), 986-993.
43. Ryu, J.R., Jin, B.S., Suh, M.J., Yoo, Y.S., Yoon, S.H., Woo, E.R., and Yu, Y.G. (1999) Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. Biochem. Biophys. Res. Commun., 265 (3), 625-629.
44. Kliger, Y., Gallo, S.A., Peisajovich, S.G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., and Shai, Y. (2001) Mode of action of an antiviral peptide from HIV-1 Inhibition at a post-lipid mixing stage. J. Biol. Chem., 276 (2), 1391-1397.
45. Munoz-Barroso, I., Salzwedel, K., Hunter, E., and Blumenthal, R. (1999) Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J. Virol., 73 (7), 6089-6092.
46. Mobley, P.W., Pilpa, R., Brown, C., Waring, A.J., and Gordon, L.M. (2001) Membrane-perturbing domains of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses., 17 (4), 311-327.
47. Alam, S.M., Paleos, C.A., Liao, H.X., Scearce, R., Robinson, J., and Haynes, B.F. (2004) An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res. Hum. Retroviruses., 20 (8), 836-845.
48. Veiga, A.S., Santos, N.C., and Castanho, M.A. (2006) An insight on the leading HIV entry inhibitors. Recent. Pat. Antiinfect. Drug Discov., 1 (1), 67-73.
49. Eron, J.J., Gulick, R.M., Bartlett, J.A., Merigan, T., Arduino, R., Kilby, J.M., Yangco, B., Diers, A., Drobnes, C., DeMasi, R., Greenberg, M., Melby, T., Raskino, C., Rusnak, P., Zhang, Y., Spence, R., and Miralles, G.D. (2004) Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis., 189 (6), 1075-1083.
50. Lalezari, J.P., Bellos, N.C., Sathasivam, K., Richmond, G.J., Cohen, C.J., Myers, R.A. Jr, Henry, D.H., Raskino, C., Melby, T., Murchison, H., Zhang, Y., Spence, R., Greenberg, M.L., Demasi, R. A., and Miralles, G.D. (2005) T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtidecontaining treatment regimen. J. Infect. Dis., 191 (7), 1155-1163.
51. Pan, C., Liu, S., and Jiang, S. (2010) HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J. Formos. Med. Assoc., 109 (2), 94-105.
52. He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., and Zhang, L. (2008) Design and evaluation of Sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem., 283 (17), 11126-11134.
53. Franquelim, H.G., Loura, L.M., Santos, N.C., and Castanho, M.A. (2008) Sifuvirtide screens rigid membrane surfaces. Establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J. Am. Chem. Soc., 130 (19), 6215-6223.
54. Franquelim, H.G., Veiga, A.S., Weissmuller, G., Santos, N.C., and Castanho, M.A. (2010) Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor Sifuvirtide towards phosphatidylcholine-rich rigid membranes. Biochim. Biophys. Acta, 1798 (6), 1234-1243.
55. Wang, R.R., Yang, L.M., Wang, Y.H., Pang, W., Tam, S.C., Tien, P., and Zheng, Y.T. (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem. Biophys. Res. Commun., 382 (3), 540-544.
56. Judice, J.K., Tom, J.Y., Huang, W., Wrin, T., Vennari, J., Petropoulos, C.J., and McDowell, R.S. (1997) Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc. Natl. Acad. Sci. U. S. A., 94 (25), 13426-13430.
57. Sia, S.K., Carr, P.A., Cochran, A.G., Malashkevich, V.N., and Kim, P.S. (2002) Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A., 99 (23), 14664-14669.
58. +salt bridges in short peptides of de novo design. Proc. Natl. Acad. Sci. U. S. A., 84 (24), 8898-8902.
59. Nishikawa, H., Nakamura, S., Kodama, E., Ito, S., Kajiwara, K., Izumi, K., Sakagami, Y., Oishi, S., Ohkubo, T., Kobayashi, Y., Otaka, A., Fujii, N., and Matsuoka, M. (2009) Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int. J. Biochem. Cell Biol., 41 (4), 891-899.
60. Oishi, S., Ito, S., Nishikawa, H., Watanabe, K., Tanaka, M., Ohno, H., Izumi, K., Sakagami, Y., Kodama, E., Matsuoka, M., and Fujii, N. (2008) Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem., 51 (3), 388-391.
61. Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S.G., Oishi, S., Fujii, N., and Matsuoka, M. (2009) SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother., 53 (3), 1013-1018.
62. Dwyer, J.J., Wilson, K.L., Davison, D.K., Freel, S.A., Seedorff, J.E., Wring, S.A., Tvermoes, N.A., Matthews, T.J., Greenberg, M.L., and Delmedico, M.K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtideresistant virus. Proc. Natl. Acad. Sci. U. S. A., 104 (31), 12772-12777.
63. He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., and Dai, Q. (2008) Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol., 82 (13), 6349-6358.
64. He, Y., Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., and Dai, Q. (2008) Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A., 105 (42), 16332-16337.
65. Trivedi, V.D., Cheng, S.F., Wu, C.W., Karthikeyan, R., Chen, C.J., and Chang, D.K. (2003) The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng., 16 (4), 311-317.
66. Izumi, K., Kodama, E., Shimura, K., Sakagami, Y., Watanabe, K., Ito, S., Watabe, T., Terakawa, Y., Nishikawa, H., Sarafianos, S.G., Kitaura, K., Oishi, S., Fujii, N., and Matsuoka, M. (2009) Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J. Biol. Chem., 284 (8), 4914-4920.
67. Sia, S.K. and Kim, P.S. (2003) Protein grafting of an HIV-1-inhibiting epitope. Proc. Natl. Acad. Sci. U. S. A., 100 (17), 9756-9761.
68. Soonthornsata, B., Tian, Y.S., Utachee, P., Sapsutthipas, S., Isarangkura-na-Ayuthaya, P., Auwanit, W., Takagi, T., Ikuta, K., Sawanpanyalert, P., Kawashita, N., and Kameoka, M. (2010) Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41. Virology, 405 (1), 157-164.
69. Eckert, D.M., Malashkevich, V.N., Hong, L.H., Carr, P.A., and Kim, P.S. (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 99 (1), 103-115.
70. Welch, B.D., VanDemark, A.P., Heroux, A., Hill, C.P., and Kay, M.S. (2007) Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A., 104 (43), 16828-16833.
71. Gaston, F., Granados, G.C., Madurga, S., Rabanal, F., Lakhdar-Ghazal, F., Giralt, E., and Bahraoui, E. (2009) Development and characterization of peptidic fusion inhibitors derived from HIV-1 gp41 with partial D-amino acid substitutions. ChemMedChem., 4 (4), 570-581.
72. Deng, Y., Zheng, Q., Ketas, T.J., Moore, J.P., and Lu, M. (2007) Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry (Mosc.)., 46 (14), 4360-4369.
73. Hildinger, M., Dittmar, M.T., Schult-Dietrich, P., Fehse, B., Schnierle, B.S., Thaler, S., Stiegler, G., Welker, R., and von Laer, D. (2001) Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol., 75 (6), 3038-3042.
74. Peisajovich, S.G., Gallo, S.A., Blumenthal, R., and Shai, Y. (2003) C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J. Biol. Chem., 278 (23), 21012-21017.
75. Wexler-Cohen, Y. and Shai, Y. (2007) Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J., 21 (13), 3677-3684.
76. Zhang, H.Y., Schneider, S.E., Bray, B.L., Friedrich, P.E., Tvermoes, N.A., Mader, C.J., Whight, S.R., Niemi, T.E., Silinski, P., Picking, T., Warren, M., and Wrings, S.A. (2008) Process development of TRI-999, a fatty-acid-modified HIV fusion inhibitory peptide. Org. Process Res. Dev., 12 (1), 101-110
77. Stanfield-Oakley, S.A., Mosier, S.M., Davison, D.K., Medinas, R.J., Jin, L., Delmedico, M.K., Dwyer, J.J., Heilek-Snyder, G., and Greenberg, M.L. (2006) Next generation HIV peptide fusion inhibitors TRI-999 and TRI-1144 display enhanced activity against enfuvirtide sensitive and resistant viruses. Antivir. Ther., 11 (5), S25-S25.
78. Ingallinella, P., Bianchi, E., Ladwa, N.A., Wang, Y.J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T.J., Moore, J.P., Miller, M.D., and Pessi, A. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A., 106 (14), 5801-5806.
79. Porotto, M., Yokoyama, C.C., Palermo, L.M., Mungall, B., Aljofan, M., Cortese, R., Pessi, A., and Moscona, A. (2010) Viral entry inhibitors targeted to the membrane site of action. J. Virol., 84 (13), 6760-6768.
80. Stoddart, C.A., Nault, G., Galkina, S.A., Thibaudeau, K., Bakis, P., Bousquet-Gagnon, N., Robitaille, M., Bellomo, M., Paradis, V., Liscourt, P., Lobach, A., Rivard, M.E., Ptak, R.G., Mankowski, M.K., Bridon, D., and Quraishi, O. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem., 283 (49), 34045-34052.
81. Xie, D., Yao, C., Wang, L., Min, W., Xu, J., Xiao, J., Huang, M., Chen, B., Liu, B., Li, X., and Jiang, H. (2010) An albuminconjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob. Agents Chemother., 54 (1), 191-196.
82. Ji, C., Kopetzki, E., Jekle, A., Stubenrauch, K.G., Liu, X., Zhang, J., Rao, E., Schlothauer, T., Fischer, S., Cammack, N., Heilek, G., Ries, S., and Sankuratri, S. (2009) CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J. Biol. Chem., 284 (8), 5175-5185.
83. Baldwin, C. and Berkhout, B. (2007) HIV-1 drug-resistance and drugdependence. Retrovirology, 4, 78.
84. Bai, X., Wilson, K.L., Seedorff, J.E., Ahrens, D., Green, J., Davison, D.K., Jin, L., Stanfield-Oakley, S.A., Mosier, S.M., Melby, T.E., Cammack, N., Wang, Z., Greenberg, M.L., and Dwyer, J.J. (2008) Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and sixhelix bundle structure. Biochemistry (Mosc.), 47 (25), 6662-6670.
85. Tolstrup, M., Selzer-Plon, J., Laursen, A. L., Bertelsen, L., Gerstoft, J., Duch, M., Pedersen, F.S., and Ostergaard, L. (2007) Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS, 21 (4), 519-521.
86. Nagashima, K.A., Thompson, D.A., Rosenfield, S.I., Maddon, P.J., Dragic, T., and Olson, W.C. (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis., 183 (7), 1121-1125.
87. Tremblay, C.L., Giguel, F., Kollmann, C., Guan, Y., Chou, T.C., Baroudy, B.M., and Hirsch, M.S. (2002) Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother., 46 (5), 1336-1339.
88. Tremblay, C.L., Kollmann, C., Giguel, F., Chou, T.C., and Hirsch, M.S. (2000) Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr., 25 (2), 99-102.
89. Hrin, R., Montgomery, D.L., Wang, F., Condra, J.H., An, Z., Strohl, W.R., Bianchi, E., Pessi, A., Joyce, J.G., and Wang, Y.J. (2008) Short communication: in vitro synergy between peptides or neutralizing antibodies targeting the Nand C-terminal heptad repeats of HIV type 1 gp41. AIDS Res. Hum. Retroviruses, 24 (12), 1537-1544.
90. Pan, C., Lu, H., Qi, Z., and Jiang, S. (2009) Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first-and next-generation HIV-fusion inhibitors. AIDS, 23 (5), 639-641.
91. Pan, C., Cai, L., Lu, H., Qi, Z., and Jiang, S. (2009) Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtidesensitive and-resistant HIV type 1 strains. J. Virol., 83 (16), 7862-7872.